Specifications - Celltrion Biopharmaceutical Plant, Incheon, South Korea

Key Data
Order year	November 2002
Location	Songdo New City, Incheon, South Korea
Estimated investment	$85m
Completion	2005, validation to be carried out in early 2006 with full production by mid 2006
Expansion	Phase two of the plant to give an additional 180,000l of capacity is expected to be complete by 2010
Output chemicals	Vaccines, protein therapeutics and monoclonal antibodies
Key Players
Sponsor	Celltrion (Vaxgen is no longer involved having sold its interest in the company)
Lead engineer / designer	Fluor Enterprises, Daewoo Engineering and Construction, BioEngineering, Foster Wheeler
Other contractors	Emerson Process Management, Amersham, Millipore
Validation	Fluor Enterprises, VaxGen QA
Financing	Vaxgen (48%), Nexol and Nexol Biotech (13%), Korean Tobacco and Ginseng (13%), J. Stephen and Co Ventures (13%) and others (8%)
Featured Suppliers
Applikon Biotechnology - Bioreactor Systems